慢性自发性荨麻疹成年患者的死亡率:一项真实世界的队列研究。

IF 11.4 1区 医学 Q1 ALLERGY
Pavel Kolkhir, Katja Bieber, Tomasz Hawro, Khalaf Kridin, Marlene A Ludwig, Henning Olbrich, Martin Metz, Artem Vorobyev, Ralf J Ludwig, Marcus Maurer
{"title":"慢性自发性荨麻疹成年患者的死亡率:一项真实世界的队列研究。","authors":"Pavel Kolkhir, Katja Bieber, Tomasz Hawro, Khalaf Kridin, Marlene A Ludwig, Henning Olbrich, Martin Metz, Artem Vorobyev, Ralf J Ludwig, Marcus Maurer","doi":"10.1016/j.jaci.2024.11.036","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life-limiting, but the mortality of CSU has not been investigated.</p><p><strong>Objective: </strong>To assess all-cause mortality in CSU patients, risk for comorbidities that are leading causes of death and impact of guideline-recommended urticaria treatments on mortality rates.</p><p><strong>Methods: </strong>This is a retrospective population-based cohort study of electronic health records of 272,190 adult CSU patients and 12,728,913 non-urticaria controls from the US Collaborative TriNetx Analytics Network.</p><p><strong>Results: </strong>The study included 264,680 propensity score-matched patients with CSU (mean [SD] age, 47.5 [19.8] years; 71.5% female) and a corresponding number of non-urticaria controls. Patients with CSU had a higher three-month, one-year, and five-year all-cause mortality (hazard ratio, HR=2.09, 95% CI=1.97-2.21, HR=1.77, 95% CI=1.71-1.83, and HR=1.69, 95% CI=1.65-1.73, respectively; all p<0.0001). As compared to non-CSU controls, CSU patients exhibited higher risk and rates of the leading causes of death in the US including suicidal ideations/suicide attempts (HR=3.14, 95% CI=3.00-3.28), and malignant neoplasms (HR=2.09, 95% CI=2.02-2.16). The risk of mortality in CSU appeared to be more pronounced in White and younger patients. All-cause mortality rates at 5 years were significantly lower in CSU patients treated with second generation H1-antihistamines versus untreated patients (1.0% vs. 2.3%, HR=1.84, p<0.0001) and omalizumab-treated patients versus antihistamine-treated patients (0.7% vs. 2.6%, HR=3.99, p=0.003).</p><p><strong>Conclusion: </strong>CSU is associated with increased mortality likely due to comorbidities, especially suicide, and effective CSU treatment may reduce mortality. These findings should be investigated in additional studies, also in other populations.</p>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study.\",\"authors\":\"Pavel Kolkhir, Katja Bieber, Tomasz Hawro, Khalaf Kridin, Marlene A Ludwig, Henning Olbrich, Martin Metz, Artem Vorobyev, Ralf J Ludwig, Marcus Maurer\",\"doi\":\"10.1016/j.jaci.2024.11.036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life-limiting, but the mortality of CSU has not been investigated.</p><p><strong>Objective: </strong>To assess all-cause mortality in CSU patients, risk for comorbidities that are leading causes of death and impact of guideline-recommended urticaria treatments on mortality rates.</p><p><strong>Methods: </strong>This is a retrospective population-based cohort study of electronic health records of 272,190 adult CSU patients and 12,728,913 non-urticaria controls from the US Collaborative TriNetx Analytics Network.</p><p><strong>Results: </strong>The study included 264,680 propensity score-matched patients with CSU (mean [SD] age, 47.5 [19.8] years; 71.5% female) and a corresponding number of non-urticaria controls. Patients with CSU had a higher three-month, one-year, and five-year all-cause mortality (hazard ratio, HR=2.09, 95% CI=1.97-2.21, HR=1.77, 95% CI=1.71-1.83, and HR=1.69, 95% CI=1.65-1.73, respectively; all p<0.0001). As compared to non-CSU controls, CSU patients exhibited higher risk and rates of the leading causes of death in the US including suicidal ideations/suicide attempts (HR=3.14, 95% CI=3.00-3.28), and malignant neoplasms (HR=2.09, 95% CI=2.02-2.16). The risk of mortality in CSU appeared to be more pronounced in White and younger patients. All-cause mortality rates at 5 years were significantly lower in CSU patients treated with second generation H1-antihistamines versus untreated patients (1.0% vs. 2.3%, HR=1.84, p<0.0001) and omalizumab-treated patients versus antihistamine-treated patients (0.7% vs. 2.6%, HR=3.99, p=0.003).</p><p><strong>Conclusion: </strong>CSU is associated with increased mortality likely due to comorbidities, especially suicide, and effective CSU treatment may reduce mortality. These findings should be investigated in additional studies, also in other populations.</p>\",\"PeriodicalId\":14936,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":11.4000,\"publicationDate\":\"2024-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jaci.2024.11.036\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaci.2024.11.036","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:慢性自发性荨麻疹(CSU)是一种常见的使人衰弱的疾病,人们普遍认为它不会危及生命,但对CSU的死亡率尚未进行调查:目的:评估慢性荨麻疹患者的全因死亡率、作为主要死因的合并症风险以及指南推荐的荨麻疹治疗方法对死亡率的影响:这是一项基于人群的回顾性队列研究,研究对象是美国TriNetx分析协作网络中的272,190名成年CSU患者和12,728,913名非荨麻疹对照者的电子健康记录:研究包括 264,680 名倾向得分匹配的 CSU 患者(平均 [SD] 年龄为 47.5 [19.8] 岁;71.5% 为女性)和相应数量的非荨麻疹对照组。CSU患者的三个月、一年和五年全因死亡率较高(危险比分别为HR=2.09(95% CI=1.97-2.21)、HR=1.77(95% CI=1.71-1.83)和HR=1.69(95% CI=1.65-1.73);均为pConclusion):CSU与死亡率升高有关,其原因可能是合并症,尤其是自杀,而有效的CSU治疗可降低死亡率。这些发现应在更多的研究中进行调查,也应在其他人群中进行调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study.

Background: Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life-limiting, but the mortality of CSU has not been investigated.

Objective: To assess all-cause mortality in CSU patients, risk for comorbidities that are leading causes of death and impact of guideline-recommended urticaria treatments on mortality rates.

Methods: This is a retrospective population-based cohort study of electronic health records of 272,190 adult CSU patients and 12,728,913 non-urticaria controls from the US Collaborative TriNetx Analytics Network.

Results: The study included 264,680 propensity score-matched patients with CSU (mean [SD] age, 47.5 [19.8] years; 71.5% female) and a corresponding number of non-urticaria controls. Patients with CSU had a higher three-month, one-year, and five-year all-cause mortality (hazard ratio, HR=2.09, 95% CI=1.97-2.21, HR=1.77, 95% CI=1.71-1.83, and HR=1.69, 95% CI=1.65-1.73, respectively; all p<0.0001). As compared to non-CSU controls, CSU patients exhibited higher risk and rates of the leading causes of death in the US including suicidal ideations/suicide attempts (HR=3.14, 95% CI=3.00-3.28), and malignant neoplasms (HR=2.09, 95% CI=2.02-2.16). The risk of mortality in CSU appeared to be more pronounced in White and younger patients. All-cause mortality rates at 5 years were significantly lower in CSU patients treated with second generation H1-antihistamines versus untreated patients (1.0% vs. 2.3%, HR=1.84, p<0.0001) and omalizumab-treated patients versus antihistamine-treated patients (0.7% vs. 2.6%, HR=3.99, p=0.003).

Conclusion: CSU is associated with increased mortality likely due to comorbidities, especially suicide, and effective CSU treatment may reduce mortality. These findings should be investigated in additional studies, also in other populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信